Downloads
Abstract
Objective: The purpose of this study was to evaluate the feasibility and the effect of the laparoscopic debulking surgery in the treatment of advanced ovarian cancer after neoadjuvant chemotherapy.
Methods: We performed a retrospective review of laparoscopic approach in patients with histologically confirmed epithelial ovarian cancer (International Federation of Gynaecology Obstetrics stages IIIC-IV) who received 3 courses of neoadjuvant chemo-therapy, from January 2012 to January 2018, at the Department of Obstetrics and Gynaecology, Hue Central Hospital.
Results: A total of 32 patients were included. The median age was 51 years (range, 25-67 years), median body mass index was 24.4 kg/m2 (range, 20-41 kg/m2). All patients had good clinical response to 3 cycles of neoadjuvant chemotherapy. Most women underwent a complete debulking surgery with no residual disease (56.25%). The median operating time was 150 minutes (range, 75-330 minutes), the median blood loss was 85 mL (range, 55-220 mL). The median number of removed pelvic lymph nodes was 14 (range, 09-21). There was 1 (3.13%) intraoperative complication and 2 (6.26%) postoperative short-term complications. The median length of hospital stay was 5 days (range, 4-13 days). The median follow-up was 18 months (range, 5-56 months). Twenty-eight patients are free from recurrence at this time.
Conclusions: Laparoscopic cytoreduction when performed by skilled surgeons, seems feasible and may decrease the impact of aggressive surgery in patients with advanced ovarian cancer after neoadjuvant chemotherapy, is an attractive alternative to the traditional abdominal surgical approach. The significant advantages of this approach are less invasive surgery, less blood loss during surgery, short recovery time.
References
Vasileios D. Sioulas, Maria B. Schiavone, DavidKadouri, Oliver Zivanovic, et al. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?.Gynecol Oncol, 2017; 97:640-651.
Gennaro Daniele, Domenica Lorusso, Giovanni Scambia, Sabrina C. Cecere, MariaOrnellaNicoletto. Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. Gynecol Oncol, 2016, 345: 543-601.
Weihong Yang, Zhongping Cheng, Hong Dai, Changchun Long, Hailun Liu, et al. Laparoscopic-based score assessment combined with a multiple disciplinary team in management of recurrent ovarian cancer: A single-center prospective study for personalized surgical therapy. Medicine, 2017. 234: 457-489.
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CACancer J Clin. 2014;64:9-29.
Carney ME, Lancaster JM, Ford C, et al. A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol. Oncol. 2002; 84: 36-42.
Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943-953.
Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol. 1998;71:431-436.
Liu CS, Nagarsheth NP, Nezhat FR. Laparoscopy and ovarian cancer: a paradigm change in the management of ovarian cancer? J Minim Invasive Gynecol. 2009;16:250-262.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240:205–13.
Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
Barletta F, Corrado G, Vizza E. Use of a new instruments in the management of total laparoscopic radical hysterectomy (TLRH). J Minim Invasive Gynecol. 2014;21:S89.
Amara DP, Nezhat C, Teng NN, et al. Operative laparoscopy in the management of ovarian cancer. Surg Laparosc Endosc. 1996;6:38-45.
Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004;94:650-654.
Da Costa Miranda V, de Souza Fede A B, Dos Anjos CH, et al. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014;132:287-291.
Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med. 2004;351:2489-2497.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 Journal of Clinical Medicine Hue Central Hospital